Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1

Table 2

Response to treatment by per-protocol analysis of evaluable patients ( = 29).

Variable	Number of patients (%)
CR	2 (6.9)
PR	3 (10.3)
SD	12 (41.4)
PD	12 (41.4)
Overall response (CR + PR), %	17.2
Disease control (CR + PR + SD), %	58.6

CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.